6URH
| |
6MEG
| Crystal structure of human monoclonal antibody HEPC46 | Descriptor: | antibody HEPC46 Heavy Chain, antibody HEPC46 Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J. | Deposit date: | 2018-09-06 | Release date: | 2018-11-21 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.41 Å) | Cite: | HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host Microbe, 24, 2018
|
|
6MEH
| |
6MEE
| Crystal structure of broadly neutralizing antibody HEPC74 | Descriptor: | antibody HEPC74 Heavy Chain, antibody HEPC74 Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J. | Deposit date: | 2018-09-06 | Release date: | 2018-11-21 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (1.36 Å) | Cite: | HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host Microbe, 24, 2018
|
|
6MEJ
| |
6MEK
| |
6MEF
| Crystal structure of broadly neutralizing antibody AR3C | Descriptor: | antibody AR3C Heavy Chain, antibody AR3C Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J. | Deposit date: | 2018-09-06 | Release date: | 2018-11-21 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (2.9 Å) | Cite: | HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host Microbe, 24, 2018
|
|
6MEI
| |
6MED
| Crystal structure of broadly neutralizing antibody HEPC3 | Descriptor: | SULFATE ION, antibody HEPC3 Heavy Chain, antibody HEPC3 Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J. | Deposit date: | 2018-09-06 | Release date: | 2018-11-21 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (2.04 Å) | Cite: | HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Cell Host Microbe, 24, 2018
|
|
8W0X
| |
8W0Y
| |
8W0W
| |
8W0V
| |
7U0C
| Crystal structure of broadly neutralizing antibody HEPC3.4 | Descriptor: | HEPC3.4 Fab Heavy Chain, HEPC3.4 Fab Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J. | Deposit date: | 2022-02-17 | Release date: | 2022-06-08 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (3.3 Å) | Cite: | Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nat Commun, 13, 2022
|
|
7U0B
| Crystal structure of broadly neutralizing antibody HEPC3.1 | Descriptor: | HEPC3.1 Fab Heavy Chain, HEPC3.1 Fab Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J. | Deposit date: | 2022-02-17 | Release date: | 2022-06-08 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.79 Å) | Cite: | Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nat Commun, 13, 2022
|
|
7RFB
| Crystal structure of broadly neutralizing antibody mAb1198 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... | Authors: | Flyak, A.I, Bjorkman, P.J. | Deposit date: | 2021-07-14 | Release date: | 2022-01-12 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. Immunity, 55, 2022
|
|
7RFC
| |
7N3E
| Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C032 | Descriptor: | C032 Fab Heavy Chain, C032 Fab Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | Deposit date: | 2021-06-01 | Release date: | 2021-08-04 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.06 Å) | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 54, 2021
|
|
7N3G
| Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C098 | Descriptor: | C098 Fab Heavy Chain, C098 Fab Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | Deposit date: | 2021-06-01 | Release date: | 2021-08-04 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (1.42 Å) | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 54, 2021
|
|
7N3F
| Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C080 | Descriptor: | C080 Fab Heavy Chain, C080 Fab Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | Deposit date: | 2021-06-01 | Release date: | 2021-08-04 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (1.9 Å) | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 54, 2021
|
|
7N3I
| Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment C098 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, C098 Fab heavy chain, C098 Fab light chain, ... | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | Deposit date: | 2021-06-01 | Release date: | 2021-08-04 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.03 Å) | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 54, 2021
|
|
7N3H
| Crystal structure of an anti-SARS-CoV-2 human neutralizing antibody Fab fragment C099 | Descriptor: | C099 Fab Heavy Chain, C099 Fab Light Chain | Authors: | Flyak, A.I, Bjorkman, P.J, Barnes, C.O. | Deposit date: | 2021-06-01 | Release date: | 2021-08-04 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (1.26 Å) | Cite: | Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity, 54, 2021
|
|
6BP2
| Therapeutic human monoclonal antibody MR191 bound to a marburgvirus glycoprotein | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein, Envelope glycoprotein GP2, ... | Authors: | King, L.B, Fusco, M.L, Flyak, A.I, Ilinykh, P.A, Huang, K, Gunn, B, Kirchdoerfer, R.N, Hastie, K.M, Sangha, A.K, Meiler, J, Alter, G, Bukreyev, A, Crowe, J.E.J, Saphire, E.O. | Deposit date: | 2017-11-21 | Release date: | 2018-01-17 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (3.172 Å) | Cite: | The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. Cell Host Microbe, 23, 2018
|
|
5UQY
| Crystal structure of Marburg virus GP in complex with the human survivor antibody MR78 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ENVELOPE GLYCOPROTEIN GP1, ... | Authors: | Hashiguchi, T, Fusco, M.L, Hastie, K.M, Bomholdt, Z.A, Lee, J.E, Flyak, A.I, Matsuoka, R, Kohda, D, Yanagi, Y, Hammel, M, Crowe, J.E, Saphire, E.O. | Deposit date: | 2017-02-08 | Release date: | 2017-03-01 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (3.6 Å) | Cite: | Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell, 160, 2015
|
|
5KEM
| EBOV sGP in complex with variable Fab domains of IgGs c13C6 and BDBV91 | Descriptor: | BDBV91 variable Fab domain heavy chain, BDBV91 variable Fab domain light chain, Ebola secreted glycoprotein, ... | Authors: | Pallesen, J, Murin, C.D, de Val, N, Cottrell, C.A, Hastie, K.M, Turner, H.L, Fusco, M.L, Flyak, A.I, Zeitlin, L, Crowe Jr, J.E, Andersen, K.G, Saphire, E.O, Ward, A.B. | Deposit date: | 2016-06-09 | Release date: | 2016-09-07 | Last modified: | 2019-12-11 | Method: | ELECTRON MICROSCOPY (5.5 Å) | Cite: | Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol, 1, 2016
|
|